# Tag: HAPV3

- [Hapvida Says Review of 947,000 Members Aims to Rebalance Contracts After ANS Injunction](https://brazilstockguide.com/insights/hapvida-947000-members-review-ans-contracts/) (2026-08-20): Health operator says it will negotiate with delinquent clients and large loss-making corporate plans; regulator has requested explanations.
- [Hapvida reviews contracts, cuts units and puts R$4 billion in annual purchases under review to restore margins](https://brazilstockguide.com/insights/hapvida-r4-billion-purchases-restore-margins/) (2026-08-13): Brazil’s largest health plan operator is shedding idle capacity, renegotiating supplier agreements, reviewing its membership book and preparing asset sales to strengthen cash generation and reduce debt.
- [Hapvida Revives NotreDame Brand in Push Into Premium Health Plans](https://brazilstockguide.com/insights/hapvida-notredame-premium-health-plans/) (2026-07-27): New offering will provide access to Einstein, Sírio-Libanês and HCor, signaling a shift from the insurer’s vertically integrated model; rollout will begin in São Paulo and Rio de Janeiro.
- [Listed Healthcare Companies Create Nearly 80,000 Jobs, Expanding Headcount by 48% Since 2019](https://brazilstockguide.com/insights/listed-healthcare-companies-create-nearly-80000-jobs-expanding-headcount-by-48-since-2019/) (2026-06-29): A BTG Pactual survey shows ten listed healthcare companies increased their combined workforce from about 166,000 to 245,000 employees; Hapvida and Rede D’Or led the expansion.
- [Hapvida Expands Research Center, Targets High-Complexity Therapies](https://brazilstockguide.com/insights/hapvida-clinical-research-center-pharma-partnerships/) (2026-06-25): With 13 active studies, the new unit strengthens Hapvida’s push to turn its patient scale into a clinical-research platform.
- [After the Storm, Hapvida Eases Credit Stress](https://brazilstockguide.com/insights/hapvida-eases-credit-stress/) (2026-05-22): The health plan operator’s debentures rallied after Q1 results, while new management, a revamped board and minority-shareholder pressure open room for a recovery.
- [Hapvida cuts medical costs, but still owes investors a turnaround](https://brazilstockguide.com/insights/hapvida-cuts-medical-costs-but-still-owes-investors-a-turnaround/) (2026-05-11): Lower medical expenses helped margins in Q1 2026, but health plan membership losses, a net loss and higher leverage kept the recovery incomplete.
- [Amil Leads March Beneficiary Gains as Bradsaúde Wins the Quarter](https://brazilstockguide.com/insights/amil-gains-lives-march-bradsaude-health-plan-growth-q1/) (2026-05-11): ANS data compiled by BTG Pactual show a better March for Brazil’s health plan operators, but the recovery remains selective.
- [Hapvida controllers raise stake to shield board control](https://brazilstockguide.com/insights/hapvida-controlling-shareholders-increase-stake/) (2026-04-24): Family lifts ownership to about 55% of capital — nearly 59% excluding treasury shares — using shares, lending and derivatives ahead of key vote.
- [Hapvida treats asset sales as “a possibility” under investor pressure](https://brazilstockguide.com/insights/jorge-pinheiro-hapvida-ceo-2/) (2026-04-06): After Squadra letter, Jorge Pinheiro confirms expected CEO exit but avoids concrete measures, frustrating the market.

Next page: https://brazilstockguide.com/tag/hapv3/page/2/?format=markdown